Chromogranin A as an Alternative to 5-Hydroxyindoleacetic Acid in the Evaluation of Symptoms during Treatment of Patients with Neuroendocrine Tumors
Background: Urinary 5-HIAA excretion is a well-known marker in neuroendocrine tumors (NETs), but it has a low sensitivity and the 24-hour collection is inconvenient for patients. Chromogranin A (CgA) is a promising marker, but a thorough evaluation during follow-up is still lacking. Methods: 39 pati...
Gespeichert in:
| Veröffentlicht in: | Neuroendocrinology 2009-01, Vol.89 (3), p.296-301 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 301 |
|---|---|
| container_issue | 3 |
| container_start_page | 296 |
| container_title | Neuroendocrinology |
| container_volume | 89 |
| creator | Korse, Catharina M. Bonfrer, Johannes M.G. Aaronson, Neil K. Hart, Augustinus A.M. Taal, Babs G. |
| description | Background: Urinary 5-HIAA excretion is a well-known marker in neuroendocrine tumors (NETs), but it has a low sensitivity and the 24-hour collection is inconvenient for patients. Chromogranin A (CgA) is a promising marker, but a thorough evaluation during follow-up is still lacking. Methods: 39 patients with metastatic gastrointestinal NETs were monitored during treatment with the long-acting octreotide SandostatinLAR®. A comparison was made between serum CgA and urinary 5-HIAA in relation to quality of life (HRQL) assessed by the EORTC QLQ-C30 questionnaire, supplemented with questions specific to carcinoid symptoms. Survival analyses were performed to examine the association between the markers and survival time. Results: Correlations were found between CgA and physical functioning (p = 0.01) and quality of life (p = 0.03), while no significant correlations were observed between 5-HIAA levels and any of the self-reported health outcomes. Cox regression showed an association between CgA levels and survival time (p = 0.02), while no significant association was observed between 5-HIAA levels and survival time. Conclusion: Stronger correlations of CgA compared to 5-HIAA with physical functioning and wellbeing, the convenience of measuring in blood, as well as the prognostic value of CgA for survival, makes CgA the recommended marker in the management of patients with metastatic NETs. |
| doi_str_mv | 10.1159/000162876 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_162876</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20920100</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-f3d396188307cdbf2073e144e7d76b72757e5fd167e548a7ebb87ad9c728d80f3</originalsourceid><addsrcrecordid>eNqF0U9rFDEYBvAgit1WD95FglDBw2j-zSQ5Lku1QlHB9Txkknd2U2cma5Kp7vfwA5tllxa8eHoD-eUJyYPQC0reUVrr94QQ2jAlm0doQQXjFaFaPEYLQpiquOL1GTpP6bYwpjl7is6oUoJoXS_Qn9U2hjFsopn8hJfYJGzKHDLEyWR_BzgHXFfXexfD772fXBjAWMje4qX1DpdDeQv46s4Mc_FhwqHH3_bjLocxYTdHP23wOoLJI0z5sPm1sLJM-JfPW_wZ5higxNoiAa_nMcT0DD3pzZDg-WleoO8frtar6-rmy8dPq-VNZblmueq547opb-FEWtf1jEgOVAiQTjadZLKWUPeONmUIZSR0nZLGaSuZcor0_AK9OebuYvg5Q8rt6JOFYTAThDm1jaScCyX-CxnRjFBCCnz9D7wNc_nJoRgpat1wqgp6e0Q2hpQi9O0u-tHEfUtJeyi0vS-02FenwLkbwT3IU4MFXJ6ASdYMfSnS-nTvGOWs1vJw6cuj-2HiBuJD0PGevzhVseE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>274596318</pqid></control><display><type>article</type><title>Chromogranin A as an Alternative to 5-Hydroxyindoleacetic Acid in the Evaluation of Symptoms during Treatment of Patients with Neuroendocrine Tumors</title><source>MEDLINE</source><source>Karger Journals Complete</source><source>Alma/SFX Local Collection</source><creator>Korse, Catharina M. ; Bonfrer, Johannes M.G. ; Aaronson, Neil K. ; Hart, Augustinus A.M. ; Taal, Babs G.</creator><creatorcontrib>Korse, Catharina M. ; Bonfrer, Johannes M.G. ; Aaronson, Neil K. ; Hart, Augustinus A.M. ; Taal, Babs G.</creatorcontrib><description>Background: Urinary 5-HIAA excretion is a well-known marker in neuroendocrine tumors (NETs), but it has a low sensitivity and the 24-hour collection is inconvenient for patients. Chromogranin A (CgA) is a promising marker, but a thorough evaluation during follow-up is still lacking. Methods: 39 patients with metastatic gastrointestinal NETs were monitored during treatment with the long-acting octreotide SandostatinLAR®. A comparison was made between serum CgA and urinary 5-HIAA in relation to quality of life (HRQL) assessed by the EORTC QLQ-C30 questionnaire, supplemented with questions specific to carcinoid symptoms. Survival analyses were performed to examine the association between the markers and survival time. Results: Correlations were found between CgA and physical functioning (p = 0.01) and quality of life (p = 0.03), while no significant correlations were observed between 5-HIAA levels and any of the self-reported health outcomes. Cox regression showed an association between CgA levels and survival time (p = 0.02), while no significant association was observed between 5-HIAA levels and survival time. Conclusion: Stronger correlations of CgA compared to 5-HIAA with physical functioning and wellbeing, the convenience of measuring in blood, as well as the prognostic value of CgA for survival, makes CgA the recommended marker in the management of patients with metastatic NETs.</description><identifier>ISSN: 0028-3835</identifier><identifier>EISSN: 1423-0194</identifier><identifier>DOI: 10.1159/000162876</identifier><identifier>PMID: 18840995</identifier><identifier>CODEN: NUNDAJ</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Carcinoid Tumor - diagnosis ; Chromogranin A - blood ; Female ; Follow-Up Studies ; Fundamental and applied biological sciences. Psychology ; Gastrointestinal Neoplasms - diagnosis ; Gastrointestinal Neoplasms - drug therapy ; Gastrointestinal Neoplasms - metabolism ; Humans ; Hydroxyindoleacetic Acid - urine ; Male ; Middle Aged ; Neoplasm Metastasis ; Neuroendocrine Tumors ; Neuroendocrine Tumors - diagnosis ; Neuroendocrine Tumors - drug therapy ; Neuroendocrine Tumors - metabolism ; Octreotide - analogs & derivatives ; Octreotide - therapeutic use ; Quality of Life ; Survival Analysis ; Vertebrates: endocrinology</subject><ispartof>Neuroendocrinology, 2009-01, Vol.89 (3), p.296-301</ispartof><rights>2008 S. Karger AG, Basel</rights><rights>2009 INIST-CNRS</rights><rights>Copyright (c) 2009 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-f3d396188307cdbf2073e144e7d76b72757e5fd167e548a7ebb87ad9c728d80f3</citedby><cites>FETCH-LOGICAL-c392t-f3d396188307cdbf2073e144e7d76b72757e5fd167e548a7ebb87ad9c728d80f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21325978$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18840995$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Korse, Catharina M.</creatorcontrib><creatorcontrib>Bonfrer, Johannes M.G.</creatorcontrib><creatorcontrib>Aaronson, Neil K.</creatorcontrib><creatorcontrib>Hart, Augustinus A.M.</creatorcontrib><creatorcontrib>Taal, Babs G.</creatorcontrib><title>Chromogranin A as an Alternative to 5-Hydroxyindoleacetic Acid in the Evaluation of Symptoms during Treatment of Patients with Neuroendocrine Tumors</title><title>Neuroendocrinology</title><addtitle>Neuroendocrinology</addtitle><description>Background: Urinary 5-HIAA excretion is a well-known marker in neuroendocrine tumors (NETs), but it has a low sensitivity and the 24-hour collection is inconvenient for patients. Chromogranin A (CgA) is a promising marker, but a thorough evaluation during follow-up is still lacking. Methods: 39 patients with metastatic gastrointestinal NETs were monitored during treatment with the long-acting octreotide SandostatinLAR®. A comparison was made between serum CgA and urinary 5-HIAA in relation to quality of life (HRQL) assessed by the EORTC QLQ-C30 questionnaire, supplemented with questions specific to carcinoid symptoms. Survival analyses were performed to examine the association between the markers and survival time. Results: Correlations were found between CgA and physical functioning (p = 0.01) and quality of life (p = 0.03), while no significant correlations were observed between 5-HIAA levels and any of the self-reported health outcomes. Cox regression showed an association between CgA levels and survival time (p = 0.02), while no significant association was observed between 5-HIAA levels and survival time. Conclusion: Stronger correlations of CgA compared to 5-HIAA with physical functioning and wellbeing, the convenience of measuring in blood, as well as the prognostic value of CgA for survival, makes CgA the recommended marker in the management of patients with metastatic NETs.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Carcinoid Tumor - diagnosis</subject><subject>Chromogranin A - blood</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gastrointestinal Neoplasms - diagnosis</subject><subject>Gastrointestinal Neoplasms - drug therapy</subject><subject>Gastrointestinal Neoplasms - metabolism</subject><subject>Humans</subject><subject>Hydroxyindoleacetic Acid - urine</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Neuroendocrine Tumors</subject><subject>Neuroendocrine Tumors - diagnosis</subject><subject>Neuroendocrine Tumors - drug therapy</subject><subject>Neuroendocrine Tumors - metabolism</subject><subject>Octreotide - analogs & derivatives</subject><subject>Octreotide - therapeutic use</subject><subject>Quality of Life</subject><subject>Survival Analysis</subject><subject>Vertebrates: endocrinology</subject><issn>0028-3835</issn><issn>1423-0194</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqF0U9rFDEYBvAgit1WD95FglDBw2j-zSQ5Lku1QlHB9Txkknd2U2cma5Kp7vfwA5tllxa8eHoD-eUJyYPQC0reUVrr94QQ2jAlm0doQQXjFaFaPEYLQpiquOL1GTpP6bYwpjl7is6oUoJoXS_Qn9U2hjFsopn8hJfYJGzKHDLEyWR_BzgHXFfXexfD772fXBjAWMje4qX1DpdDeQv46s4Mc_FhwqHH3_bjLocxYTdHP23wOoLJI0z5sPm1sLJM-JfPW_wZ5higxNoiAa_nMcT0DD3pzZDg-WleoO8frtar6-rmy8dPq-VNZblmueq547opb-FEWtf1jEgOVAiQTjadZLKWUPeONmUIZSR0nZLGaSuZcor0_AK9OebuYvg5Q8rt6JOFYTAThDm1jaScCyX-CxnRjFBCCnz9D7wNc_nJoRgpat1wqgp6e0Q2hpQi9O0u-tHEfUtJeyi0vS-02FenwLkbwT3IU4MFXJ6ASdYMfSnS-nTvGOWs1vJw6cuj-2HiBuJD0PGevzhVseE</recordid><startdate>20090101</startdate><enddate>20090101</enddate><creator>Korse, Catharina M.</creator><creator>Bonfrer, Johannes M.G.</creator><creator>Aaronson, Neil K.</creator><creator>Hart, Augustinus A.M.</creator><creator>Taal, Babs G.</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20090101</creationdate><title>Chromogranin A as an Alternative to 5-Hydroxyindoleacetic Acid in the Evaluation of Symptoms during Treatment of Patients with Neuroendocrine Tumors</title><author>Korse, Catharina M. ; Bonfrer, Johannes M.G. ; Aaronson, Neil K. ; Hart, Augustinus A.M. ; Taal, Babs G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-f3d396188307cdbf2073e144e7d76b72757e5fd167e548a7ebb87ad9c728d80f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Carcinoid Tumor - diagnosis</topic><topic>Chromogranin A - blood</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gastrointestinal Neoplasms - diagnosis</topic><topic>Gastrointestinal Neoplasms - drug therapy</topic><topic>Gastrointestinal Neoplasms - metabolism</topic><topic>Humans</topic><topic>Hydroxyindoleacetic Acid - urine</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Neuroendocrine Tumors</topic><topic>Neuroendocrine Tumors - diagnosis</topic><topic>Neuroendocrine Tumors - drug therapy</topic><topic>Neuroendocrine Tumors - metabolism</topic><topic>Octreotide - analogs & derivatives</topic><topic>Octreotide - therapeutic use</topic><topic>Quality of Life</topic><topic>Survival Analysis</topic><topic>Vertebrates: endocrinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Korse, Catharina M.</creatorcontrib><creatorcontrib>Bonfrer, Johannes M.G.</creatorcontrib><creatorcontrib>Aaronson, Neil K.</creatorcontrib><creatorcontrib>Hart, Augustinus A.M.</creatorcontrib><creatorcontrib>Taal, Babs G.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Neuroendocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Korse, Catharina M.</au><au>Bonfrer, Johannes M.G.</au><au>Aaronson, Neil K.</au><au>Hart, Augustinus A.M.</au><au>Taal, Babs G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chromogranin A as an Alternative to 5-Hydroxyindoleacetic Acid in the Evaluation of Symptoms during Treatment of Patients with Neuroendocrine Tumors</atitle><jtitle>Neuroendocrinology</jtitle><addtitle>Neuroendocrinology</addtitle><date>2009-01-01</date><risdate>2009</risdate><volume>89</volume><issue>3</issue><spage>296</spage><epage>301</epage><pages>296-301</pages><issn>0028-3835</issn><eissn>1423-0194</eissn><coden>NUNDAJ</coden><abstract>Background: Urinary 5-HIAA excretion is a well-known marker in neuroendocrine tumors (NETs), but it has a low sensitivity and the 24-hour collection is inconvenient for patients. Chromogranin A (CgA) is a promising marker, but a thorough evaluation during follow-up is still lacking. Methods: 39 patients with metastatic gastrointestinal NETs were monitored during treatment with the long-acting octreotide SandostatinLAR®. A comparison was made between serum CgA and urinary 5-HIAA in relation to quality of life (HRQL) assessed by the EORTC QLQ-C30 questionnaire, supplemented with questions specific to carcinoid symptoms. Survival analyses were performed to examine the association between the markers and survival time. Results: Correlations were found between CgA and physical functioning (p = 0.01) and quality of life (p = 0.03), while no significant correlations were observed between 5-HIAA levels and any of the self-reported health outcomes. Cox regression showed an association between CgA levels and survival time (p = 0.02), while no significant association was observed between 5-HIAA levels and survival time. Conclusion: Stronger correlations of CgA compared to 5-HIAA with physical functioning and wellbeing, the convenience of measuring in blood, as well as the prognostic value of CgA for survival, makes CgA the recommended marker in the management of patients with metastatic NETs.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>18840995</pmid><doi>10.1159/000162876</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-3835 |
| ispartof | Neuroendocrinology, 2009-01, Vol.89 (3), p.296-301 |
| issn | 0028-3835 1423-0194 |
| language | eng |
| recordid | cdi_karger_primary_162876 |
| source | MEDLINE; Karger Journals Complete; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences Biomarkers, Tumor - analysis Carcinoid Tumor - diagnosis Chromogranin A - blood Female Follow-Up Studies Fundamental and applied biological sciences. Psychology Gastrointestinal Neoplasms - diagnosis Gastrointestinal Neoplasms - drug therapy Gastrointestinal Neoplasms - metabolism Humans Hydroxyindoleacetic Acid - urine Male Middle Aged Neoplasm Metastasis Neuroendocrine Tumors Neuroendocrine Tumors - diagnosis Neuroendocrine Tumors - drug therapy Neuroendocrine Tumors - metabolism Octreotide - analogs & derivatives Octreotide - therapeutic use Quality of Life Survival Analysis Vertebrates: endocrinology |
| title | Chromogranin A as an Alternative to 5-Hydroxyindoleacetic Acid in the Evaluation of Symptoms during Treatment of Patients with Neuroendocrine Tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T02%3A40%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chromogranin%20A%20as%20an%20Alternative%20to%205-Hydroxyindoleacetic%20Acid%20in%20the%20Evaluation%20of%20Symptoms%20during%20Treatment%20of%20Patients%20with%20Neuroendocrine%20Tumors&rft.jtitle=Neuroendocrinology&rft.au=Korse,%20Catharina%20M.&rft.date=2009-01-01&rft.volume=89&rft.issue=3&rft.spage=296&rft.epage=301&rft.pages=296-301&rft.issn=0028-3835&rft.eissn=1423-0194&rft.coden=NUNDAJ&rft_id=info:doi/10.1159/000162876&rft_dat=%3Cproquest_karge%3E20920100%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=274596318&rft_id=info:pmid/18840995&rfr_iscdi=true |